Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 20, 2025Cancer Research

Abstract A069: Epigenetic reprogramming restores STING pathway activation in high-grade serous ovarian cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

SRSaranya RajendranEFEman FaridICIshani Chattopadhayay

Discussion

Loading...

Member takes

Overview

Observational analysis demonstrates STING pathway restoration in ovarian cancer with DNMTi and STING agonists, suggesting a novel treatment strategy.

Key Points

  • Restoring STING expression improved antitumor immunity in high-grade serous ovarian cancer (HGSC), offering hope for better treatment outcomes.
  • Higher STING levels correlated with improved overall survival in HGSC, indicating its crucial role in tumor immunosurveillance.
  • Combination treatment of DNMT inhibitors and STING agonists significantly enhanced immune response markers CXCL10 and CCL5 in cancer cells.
  • Inhibiting DNA methylation appears to revive STING signaling, proposing a promising strategy to tackle immune evasion in HGSC.

Cite This Study

Rajendran et al. (2025) studied this question.

synapsesocial.com/papers/68d438ff713b0b5dfea7863ahttps://doi.org/10.1158/1538-7445.ovarian25-a069
View Full Paper
Ask AI
Bookmark
Share